NCT06627647 2026-03-27A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCAstraZenecaPhase 3 Recruiting878 enrolled
NCT07264816 2026-03-05A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCSichuan Baili Pharmaceutical Co., Ltd.Phase 2 Recruiting80 enrolled